Central finding #
Paper (Results): “Two registrants reported receiving care at a hospital during the week after dose 4 vaccination. The v-safe call center contacted both these registrants; one completed a VAERS report, and the other indicated the report was accidental or unrelated to vaccination.”
Paper (Summary): “Serious adverse events after mRNA booster (dose 4) are rare… Only 17 serious adverse events were reported to VAERS.”
v-safe Results stop at checkbox rates and a two-sentence hospital follow-up story. Compared to the v-safe dataset for the same presumed-immunocompromised dose-4 cohort, that understates what people typed and what MedDRA coded: pericarditis, heart attack / myocardial infarction, pulmonary embolism, stroke, and chest pain—none of which appear in the v-safe Results—while one of the two week-1 hospitalization rows is coded only as Medical counselling with a call-center outcome of Unsuccessful.
Cohort: fourth mRNA dose 12 Jan–28 Mar 2022, ≥90 days after dose 3, age ≥12 bands, ≥1 day-0–7 check-in—
about 4,068 people (paper 4,015). Week-1 hospitalization count 2 matches; rates match.
Full write-up: vsafe-analysis/mmwr/mm7128a3/anomalies_report.md.
A. Week-1 hospitalizations — under-coded / softer follow-up #
Paper (Results): both hospital reporters “were contacted”; one completed VAERS; the other said accidental/unrelated.
Day-0–7 hospitalization responses: 2 (same as the paper). One (TR2-…) carries MedDRA
Hospitalisation and GDIT Successful. The other (VJJ-…) is coded only
Medical counselling (no Hospitalisation PT) with GDIT Unsuccessful
and free text basically “Call.”
Why this matters: A lay reader would think both hospital reports were successfully handled.
The v-safe follow-up extract does not show a Successful closeout for VJJ-…, and the hospitalization
checkbox never received the standard hospitalisation medical code.
B. Emergency visits under-coded #
ER checkbox responses (day 0–7): 16 (14 registrants; paper Table 1 lists 12—close). Only 3 (~19%) carry an emergency-care– or hospitalisation-like MedDRA term; 2 have no MedDRA row at all.
C. Cardiac / clot / anaphylaxis — unpublished under “serious AEs are rare” #
Paper (Summary): “Only 17 serious adverse events were reported to VAERS.” “Serious adverse events after mRNA booster (dose 4) are rare.”
In this cohort’s MedDRA coding window: 19 Chest pain, 1 Pericarditis, 1 Myocardial infarction (“Heart attack” in free text), 1 Pulmonary embolism, 1 Cerebrovascular accident, 2 Anaphylactic reaction. Free text also includes a pericarditis narrative coded only as Chest pain.
Of 11 registrants with a Hospitalisation preferred term in the coding window, only one
is in the paper’s week-1 checkbox pair. Others are mostly day 14–30 admissions (appendicitis, MRSA, COPD/pneumonia,
surgery)—outside the week-1 count, but still in-cohort inpatient narratives the MMWR never surfaces when it
concludes serious events are rare.
Cardiac / clot / anaphylaxis MedDRA.
Serious free-text narratives.
Hospitalisation MedDRA in coding window (days since dose 4 shown).
Free text coded Unevaluable (sample).
D. Call-center follow-up among medical-care reporters #
Paper (Methods): “CDC’s v-safe call center contacts registrants who indicate that medical care was sought after vaccination…”
Among ~76 people who checked needed medical care, GDIT outcomes are roughly Successful 39 / Unsuccessful 33 / priority 2/3: 4—nearly half not Successful. Combined with the Unsuccessful outcome on one of two week-1 hospitalizations, the Methods language overstates how often follow-up closed successfully in this extract.
E. Deaths in v-safe — none under inclusion #
Paper (VAERS): one manufacturer death report (pulmonary fibrosis → respiratory failure); follow-up continuing.
This reconstructed dose-4 cohort shows no MedDRA Death or Cardiac arrest codes through 30 April 2022. The VAERS death is not contradicted by a parallel v-safe Death code here; the gap is the unpublished non-fatal serious codes above, not a hidden v-safe death tally.
Summary #
- Reporting gap: pericarditis, MI, PE, CVA, 19 Chest pain, 2 anaphylaxis unpublished next to “serious AEs are rare”
- Anomaly: both week-1 hospital reporters “contacted” with tidy outcomes — one is Medical counselling only + GDIT Unsuccessful
- Coding failure: 1 of 2 week-1 Hospitalization checkboxes lacks PT Hospitalisation; ER-like PT on ~19% of ER responses
- Context: 11 Hospitalisation PTs in coding window (mostly after day 7) with inpatient free text — never discussed
- OK: N / rates / week-1 hosp count 2 match; no in-cohort Death MedDRA
Bottom line: Compared to the v-safe dataset, this immunocompromised dose-4 brief gets the big percentages and the “two hospitalizations” count right—but it sells a “serious events are rare” message while leaving pericarditis, heart-attack, PE, stroke, and chest-pain codes off the page, under-codes one of the two week-1 hospital rows, and overstates how cleanly call-center follow-up closed for those hospital reports.